HEGER, Zbynek, Natalia Vladimirovna CERNEI, Jaromír GUMULEC, Michal MASAŘÍK, Tomas ECKSCHLAGER, Roman HRABEC, Ondřej ZÍTKA, Vojtěch ADAM and René KIZEK. Determination of common urine substances as an assay for improving prostate carcinoma diagnostics. Oncology Reports. ATHENS: SPANDIDOS PUBL LTD, 2014, vol. 31, No 4, p. 1846-1854. ISSN 1021-335X. Available from: https://dx.doi.org/10.3892/or.2014.3054.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Determination of common urine substances as an assay for improving prostate carcinoma diagnostics
Authors HEGER, Zbynek (203 Czech Republic), Natalia Vladimirovna CERNEI (498 Republic of Moldova), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution), Tomas ECKSCHLAGER (203 Czech Republic), Roman HRABEC (203 Czech Republic, belonging to the institution), Ondřej ZÍTKA (203 Czech Republic), Vojtěch ADAM (203 Czech Republic) and René KIZEK (203 Czech Republic).
Edition Oncology Reports, ATHENS, SPANDIDOS PUBL LTD, 2014, 1021-335X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.301
RIV identification code RIV/00216224:14110/14:00075838
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3892/or.2014.3054
UT WoS 000334345600046
Keywords in English PSA; immunoenzymometric assay; ion-exchange liquid chromatography; sarcosine; spectrophotometry; proline
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 7/11/2014 09:29.
Abstract
Recently, interest in the identification of non-invasive markers for prostate carcinoma detectable in the urine of patients has increased. In this study, we monitored the abundance of potential non-invasive markers of prostate carcinoma such as amino acid sarcosine, involved in the metabolism of amino acids and methylation processes, ongoing during the progression of prostate carcinoma. In addition, other potential prostate tumor markers were studied. The most significant markers, prostate-specific antigen (PSA) and free PSA (fPSA), already used in clinical diagnosis, were analyzed using an immunoenzymometric assay. Whole amino acid profiles were also determined to evaluate the status of amino acids in patient urine samples and to elucidate the possibility of their utilization for prostate carcinoma diagnosis. To obtain the maximum amount of information, the biochemical parameters were determined using various spectrophotometric methods. All results were subjected to statistical processing for revealing different correlations between the studied parameters. We observed alterations in most of the analyzed substances. Based on the results obtained, we concluded that the specificity of prostate carcinoma diagnosis could be improved by determination of common urine metabolites, since we compiled a set of tests, including the analysis of sarcosine, proline, PSA and uric acid in the urine. These metabolites were not observed in the urine obtained from healthy subjects, while their levels were elevated in all patients suffering from prostate carcinoma.
PrintDisplayed: 4/9/2024 15:45